[{"NetIncomeLossConverted_1_Q1_USD":41524000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":230551000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":243840000.0,"EarningsPerShareDiluted_1_Q1_USD":0.17,"CommonStockSharesOutstanding_0_Q1_shares":230315768.0,"StockholdersEquity_0_Q1_USD":-598973000.0,"RevenuesConverted_1_Q1_USD":717919000.0,"Assets_0_Q1_USD":9234171000.0,"CommonStockSharesConverted_0_Q1_shares":231459092.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":238671000.0,"EarningsPerShareBasic_1_Q1_USD":0.18,"Ticker":"ENDP","CIK":"1593034","name":"ENDO INTERNATIONAL PLC","OfficialName":"Endo International plc Ordinary Shares","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"640358301.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210507"}]